Overview

A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

The proposed phase III randomised trial will compare the efficacy of trastuzumab and paclitaxel with trastuzumab, paclitaxel and lapatinib in first line treatment of HER2 positive metastatic breast cancer. The investigators will also examine potential predictive biomarkers of response to trastuzumab and lapatinib in pre-treatment biopsy samples and serum samples.

Phase:

Phase 3

Details

Lead Sponsor:

Cancer Trials Ireland

Treatments:

Albumin-Bound Paclitaxel
Lapatinib
Paclitaxel
Trastuzumab